RxDoctor Payments Data

Weston Hickey, MD

Interventional Cardiology · Houston, TXNPI 1801047287

Payments from drug & device makers

$98,214in general payments, 2019–2025

Across 1,071 payments — averaging $91.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Esperion Therapeutics, Inc.$60K
  • Novo Nordisk$15K
  • Amarin Pharma, Inc.$7K
  • Medtronic$2K
  • Abbott$2K
  • Novartis$2K
  • plus $11K from 39 others

What the payments were for

  • Speaking & faculty fees$71,36673%
  • Travel & lodging$7,0927%
  • Food & beverage$19,54320%
  • Education$2130%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$98,214 in reported general payments places this provider in the 85th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$2,053,330
Medicare patients
1,204
Services billed
8,602

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Repatha SureclickEvolocumab1,064$840,731
EliquisApixaban595$682,145
OzempicSemaglutide398$428,643
XareltoRivaroxaban289$328,806
EntrestoSacubitril/Valsartan207$254,375
Droxidopa34$149,040
FarxigaDapagliflozin Propanediol136$138,425
Praluent PenAlirocumab199$128,609
NexlizetBempedoic Acid/Ezetimibe146$107,539
VascepaIcosapent Ethyl107$85,417
BrilintaTicagrelor80$67,133
MultaqDronedarone Hcl30$45,260
Repatha PushtronexEvolocumab27$24,574
Icosapent Ethyl62$21,526
EdarbiAzilsartan Medoxomil35$19,367

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$528$682,145595 claims
Novo NordiskOzempic$15,211$428,643398 claims
Johnson & JohnsonXarelto$1,115$328,806289 claims
NovartisEntresto$1,575$254,375207 claims
AstraZenecaFarxiga, Brilinta$475$205,558216 claims
Esperion Therapeutics, Inc.Nexlizet$59,940$107,539146 claims
Sanofi-aventis U.S. LLCMultaq$145$45,26030 claims
Arbor Pharmaceuticals, Inc.Edarbi, Edarbyclor$33$38,51170 claims
Boehringer IngelheimJardiance$277$19,28620 claims
Lilly USA, LLCMounjaro$83$16,94916 claims
AmgenCorlanor$706$14,15918 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 686 interventional cardiology providers in Texas.

Other interventional cardiology in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →